Bim-Bcl-2 homology 3 mimetic therapy is effective at suppressing inflammatory arthritis through the activation of myeloid cell apoptosis.

Arthritis and Rheumatism
John C ScatizziHarris Perlman

Abstract

Rheumatoid arthritis (RA) is a destructive autoimmune disease characterized by an increased inflammation in the joint. Therapies that activate the apoptotic cascade may have potential for use in RA; however, few therapeutic agents fit this category. The purpose of this study was to examine the potential of Bim, an agent that mimics the action of Bcl-2 homology 3 (BH3) domain-only proteins that have shown success in preclinical studies of cancer, in the treatment of autoimmune disease. Synovial tissues from RA and osteoarthritis patients were analyzed for the expression of Bim and CD68 using immunohistochemistry. Macrophages from Bim(-/-) mice were examined for their response to lipopolysaccharide (LPS) using flow cytometry, real-time polymerase chain reaction analysis, enzyme-linked immunosorbent assay, and immunoblotting. Bim(-/-) mice were stimulated with thioglycollate or LPS and examined for macrophage activation and cytokine production. Experimental arthritis was induced using the K/BxN serum-transfer model. A mimetic peptide corresponding to the BH3 domain of Bim (TAT-BH3) was administered as a prophylactic agent and as a therapeutic agent. Edema of the ankles and histopathologic analysis of ankle tissue sections were use...Continue Reading

References

Sep 1, 1994·The Journal of Clinical Investigation·A E KochR M Strieter
May 9, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·H PerlmanR M Pope
Jul 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·B T Wipke, P M Allen
Nov 7, 2001·The American Journal of Pathology·A R PettitE M Gravallese
Mar 14, 2003·Rheumatology International·Insa HilbersJörg Kriegsmann
Jun 10, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Brian T WipkePaul M Allen
Jul 21, 2004·Rheumatic Diseases Clinics of North America·Hongtao Liu, Richard M Pope
Sep 9, 2004·Science·Loren D WalenskyStanley J Korsmeyer
Dec 9, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nathaniel J BrownHarris Perlman
Feb 19, 2005·Nature Reviews. Immunology·Andreas Strasser
Aug 9, 2005·Current Biology : CB·Virginie PetrilliJürg Tschopp
Sep 24, 2005·European Journal of Immunology·Samuel SolomonHarald Illges
Dec 13, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hongtao LiuRichard M Pope
Feb 1, 2006·Arthritis and Rheumatism·Hoon-Suk ChaGary S Firestein
Mar 31, 2006·Clinical Rheumatology·S BusteedJ O'Connell
May 3, 2006·The American Journal of Pathology·John C ScatizziHarris Perlman
Sep 30, 2006·Arthritis and Rheumatism·Hongtao LiuRichard M Pope
Sep 30, 2006·Arthritis and Rheumatism·John C ScatizziHarris Perlman
Jan 4, 2007·The Journal of Clinical Investigation·Victoria Del Gaizo MooreAnthony Letai
Jan 6, 2007·Cell Death and Differentiation·H ZhangC Tse
Jan 9, 2007·Annals of Surgical Oncology·Hiroyuki KashiwagiWilliam G Hawkins
Jan 27, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Suzanne TrudelXiao-Yan Wen
May 2, 2007·Journal of Leukocyte Biology·Fayyaz S SutterwalaRichard A Flavell
May 19, 2007·Arthritis Research & Therapy·John C ScatizziHarris Perlman
Oct 25, 2008·Nature·Evripidis GavathiotisLoren D Walensky
Feb 4, 2009·European Journal of Immunology·John C ScatizziHarris Perlman

❮ Previous
Next ❯

Citations

Sep 24, 2009·Current Rheumatology Reports·Melissa MaversHarris Perlman
Mar 3, 2011·Cell Death & Disease·D TischnerA Villunger
Nov 10, 2010·Immunology and Cell Biology·G Jan WiegersAndreas Villunger
Sep 15, 2012·Journal of Translational Medicine·Alexander V MisharinHarris Perlman
Dec 20, 2013·Rheumatology·Karissa E CottierSalahuddin Ahmed
Mar 1, 2013·Journal of Leukocyte Biology·Qi-Quan HuangRichard M Pope
Jun 1, 2010·Rheumatic Diseases Clinics of North America·Angelica GierutRichard M Pope
Dec 5, 2015·Frontiers in Immunology·Ceri A RobertsLeonie S Taams
Jul 11, 2012·Arthritis and Rheumatism·Qi-Quan HuangRichard M Pope
Jan 17, 2014·Arthritis & Rheumatology·Qi-Quan HuangRichard M Pope
Nov 9, 2017·The Journal of Experimental Medicine·FuNien TsaiHarris Perlman
Nov 19, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Qi-Quan HuangRichard M Pope
Jul 2, 2011·Journal of Leukocyte Biology·Kate E LawlorIan P Wicks
May 5, 2020·PloS One·Juliana Falero-PerezChristine M Sorenson
Sep 26, 2015·Oncotarget·Ronit Vogt SionovZvi Granot
Aug 24, 2016·Nature Reviews. Rheumatology·Carla M CudaHarris Perlman
Sep 16, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Emily R ElliottClifford A Lowell
May 1, 2021·Biomolecules·Mary SpeirKate E Lawlor

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.